Please Wait.....
Report
Japan Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 68 Pages I Mordor Intelligence
Japan Drug Delivery Devices Market Analysis
Japan drug delivery devices market reached USD 13.04 billion in 2025 and is forecast to climb to USD 19.65 billion by 2030, expanding at an 8.55% CAGR. The main growth engines are the country's unprecedented aging profile, the rising prevalence of chronic diseases, and policy shifts that reward self-administration technologies. Injectable products currently dominate usage patterns, yet rapid gains in implantables and smart?connected formats signal a broader pivot toward sustained-release and data-enabled care. The government's fast-track pathway for Software as Medical Device (SaMD) injectors, together with National Health Insurance (NHI) reimbursement of wearables, is accelerating time-to-market for next-generation devices. Supply-side innovation is also stimulated by a noticeable "drug-loss" gap, where more than 80 therapies remain unapproved in Japan, opening opportunities for firms that can navigate complex regulatory checkpoints. Heightened competition, however, collides with workforce shortages and regional care disparities, ensuring continued demand for automation and home-based solutions.
Japan Drug Delivery Devices Market Trends and Insights
High Burden of Chronic Diseases and Aging Population
Japan counts 24 million older adults managing multiple chronic conditions. Device designers therefore prioritise simplified interfaces, reduced dosing frequency, and safety locks that accommodate limited dexterity and cognitive changes. Controlled-release implants that exploit senescence biomarkers are gaining R&D attention, positioning local firms to capture export opportunities for geriatric-friendly solutions. The demographic pressure will remain structural, supporting steady demand well beyond the forecast window.
Government Push for Home-based Care (NHI Reimbursement for Wearables)
Insurance coverage for remote consultations and selected wearables fuels investment in self-administration platforms. Yet reimbursement for disease-specific digital rehab remains incomplete, creating a patchwork that innovators must navigate. Urban uptake is strong, while rural regions still lack robust home-care staffing and IT backbones, tempering near-term volume gains. Even so, policy direction is clear: shift care from hospitals to homes to offset staff shortages.
Stringent PMDA Validation for Combination Products Increases Time-to-Market
Half of approved autoinjectors received clearance only after the parent drug's initial approval, underscoring sequential review hurdles. Foreign firms often face added uncertainty around device?drug human-factor studies, stretching timelines despite PMDA consultation programmes in Washington, DC. The resulting delay advantages incumbent domestic players with deeper regulatory know-how.
Other drivers and restraints analyzed in the detailed report include:
Fast-track Approval Pathway for SaMD-Enabled Smart Injectors / Technological Advancements and Shortage of Medical Professionals / High Up-front Cost of Electronic Pumps Limits Smaller Clinics /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectables commanded 543.25% of Japan drug delivery devices market share in 2024, sustained by broad applicability in diabetes and oncology. Autoinjector approvals climbed steadily as ergonomic designs improved safety and convenience. Meanwhile, implantables are forecast to post a 10.40% CAGR, supported by workforce shortages that favour long-acting solutions. Japan drug delivery devices market size for implantables is projected to rise sharply as developers refine biodegradable matrices that minimize replacement surgeries.
Inhalation devices are the next rising category, backed by dry-powder innovations. Transdermal patches continue to appeal to older patients who prefer painless, steady dosing. Ocular inserts and nasal pumps stay niche but attract R&D for targeted CNS or ophthalmic therapy. Competition is shifting as digital entrants challenge mechanical incumbents with sensor-equipped applicators. Investments in senescence-targeted release systems further differentiate domestic portfolios.
Injectable routes controlled 56.34% of the Japan drug delivery devices market in 2024 owing to their entrenched role in biologics delivery. The inhalation route, however, is forecast to expand at 9.08% CAGR, driven by patient-friendly triple therapies such as AstraZeneca's Breztri. Japan drug delivery devices market size for inhalation products is thus set for robust growth as formulators achieve higher lung deposition efficiency.
Transdermal pathways hold steady appeal, while oral mucosal routes gain visibility for rapid-acting pain or rescue medications. Nasal and ocular pathways remain small but could accelerate once awareness barriers drop. The route mix increasingly reflects patient autonomy goals and the search for non-invasive, home-compatible options.
Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, and More), Route of Administration (Injectable, Inhalational and More), Technology (Conventional Mechanical, Needle-Free Jet and More), Application (Diabetes Mellitus, Oncology, and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Taisei Kako Co., Ltd. / Terumo / Mitsubishi Tanabe Pharma / Otsuka Pharmaceutical Co. / Nipro / Daiichi Sankyo Co. / Beckton Dickinson / Johnson&Johnson / Cook Group / Bayer / Novartis / GlaxoSmithKline / Pfizer / Sanofi / Eli Lilly and Company / AstraZeneca / Roche / Medtronic / West Pharmaceutical Services /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Chronic Diseases and Aging Population
4.2.2 Government Push for Home-based Care (NHI Reimbursement for Wearables)
4.2.3 Fast-track Approval Pathway for SaMD-Enabled Smart Injectors
4.2.4 Rise of Biosimilars Requiring Novel Delivery Formats
4.2.5 Technological Advancements in Drug Delivery Devices
4.2.6 Shortage of Medical Professionals Creating Need for Advaced drug Delivery Devices
4.3 Market Restraints
4.3.1 Stringent PMDA Validation for Combination Products Increases Time-to-Market
4.3.2 High Up-front Cost of Electronic Pumps Limits Smaller Clinics
4.3.3 Low Patient Awareness of Nasal & Pulmonary Devices
4.3.4 Domestic CDMO Capacity Constraints for Complex Devices
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral Mucosal (Buccal & Sublingual)
5.2.5 Ocular
5.2.6 Nasal
5.3 By Technology
5.3.1 Conventional Mechanical
5.3.2 Electronic / Smart / Connected
5.3.3 Needle-free Jet
5.3.4 Controlled / Sustained-release Systems
5.4 By Application
5.4.1 Diabetes Mellitus
5.4.2 Oncology
5.4.3 Cardiovascular Disorders
5.4.4 Respiratory Diseases (Asthma, COPD)
5.4.5 Infectious Diseases (e.g., RSV, Influenza)
5.4.6 Auto-immune & Others
5.5 By End User
5.5.1 Hospitals
5.5.2 Ambulatory Surgical Centers
5.5.3 Home-care Settings
5.5.4 Retail Pharmacies & Clinics
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Taisei Kako Co., Ltd.
6.4.2 Terumo Corporation
6.4.3 Mitsubishi Tanabe Pharma
6.4.4 Otsuka Pharmaceutical Co.
6.4.5 Nipro Corporation
6.4.6 Daiichi Sankyo Co.
6.4.7 Becton, Dickinson and Company
6.4.8 Johnson & Johnson
6.4.9 Cook Medical LLC
6.4.10 Bayer AG
6.4.11 Novartis AG
6.4.12 GlaxoSmithKline plc
6.4.13 Pfizer Inc.
6.4.14 Sanofi SA
6.4.15 Eli Lilly and Company
6.4.16 AstraZeneca plc
6.4.17 Roche Holding AG
6.4.18 Medtronic plc
6.4.19 West Pharmaceutical Services
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security